FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

RR Ruffolo

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Concepts & Ideas

Drug Dose Response Relationship

Anatomy

Vascular Smooth Muscle

Co-author Network

Publications

TOP 3
Diane Naselsky; D Ashton; RR Ruffolo; J Paul Hieble
Rabbit alpha2-adrenoceptors: both platelets and adipocytes have alpha2A-pharmacology.
Feng Gao; J Chen; Bernard L Lopez; Theodore A Christopher; J Gu; PG Lysko; RR Ruffolo; Eliot ohlstein; Xin L Ma; Tian-Li Yue
Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model.
PG Lysko; Christine L Webb; Juan-li Gu; Eliot ohlstein; RR Ruffolo; Tian-Li Yue
A comparison of carvedilol and metoprolol antioxidant activities in vitro.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of RR Ruffolo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2001: Diane Naselsky; D Ashton; RR Ruffolo; J Paul Hieble
Rabbit alpha2-adrenoceptors: both platelets and adipocytes have alpha2A-pharmacology.
The Journal of pharmacology and experimental therapeutics 2001;298(1):219-25.
2000: Feng Gao; J Chen; Bernard L Lopez; Theodore A Christopher; J Gu; PG Lysko; RR Ruffolo; Eliot ohlstein; Xin L Ma; Tian-Li Yue
Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model.
European journal of pharmacology 2000;406(1):109-16.
2000: PG Lysko; Christine L Webb; Juan-li Gu; Eliot ohlstein; RR Ruffolo; Tian-Li Yue
A comparison of carvedilol and metoprolol antioxidant activities in vitro.
Journal of cardiovascular pharmacology 2000;36(2):277-81.
2000: Eliot ohlstein; RR Ruffolo; John D Elliott
Drug discovery in the next millennium.
Annual review of pharmacology and toxicology 2000;40():177-91.
1999: David P Brooks; Eliot ohlstein; RR Ruffolo
Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data.
American heart journal 1999;138(3 Pt 2):246-51.
1999: Tian-Li Yue; Eliot ohlstein; RR Ruffolo
Apoptosis: a potential target for discovering novel therapies for cardiovascular diseases.
Current opinion in chemical biology 1999;3(4):474-80.
1999: David P Brooks; RR Ruffolo
Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1999;17(2):S27-32.
1999: J Paul Hieble; D C Kolpak; Gerald P McCafferty; RR Ruffolo; Rodolfo Testa; Amedeo Leonardi
Effects of alpha1-adrenoceptor antagonists on agonist and tilt-induced changes in blood pressure: relationships to uroselectivity.
European journal of pharmacology 1999;373(1):51-62.
1999: Robert N Willette; Nambi Aiyar; Tian-Li Yue; MP Mitchell; Jyoti Disa; B L Storer; Diane Naselsky; JM Stadel; Eliot ohlstein; RR Ruffolo
In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats.
The Journal of pharmacology and experimental therapeutics 1999;289(1):48-53.
1999: RR Ruffolo; J Paul Hieble
Adrenoceptor pharmacology: urogenital applications.
European urology 1999;36 Suppl 1():17-22.
1998: H Brunvand; G Liu; X L Ma; Tian-Li Yue; RR Ruffolo; Giora Z Feuerstein
SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits.
European journal of pharmacology 1998;356(2-3):193-8.
1998: M Gellai; G F Schreiner; RR Ruffolo; T Fletcher; R DeWolf; David P Brooks
CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1191-6.
1998: G Feuerstein; Tian-Li Yue; X Ma; RR Ruffolo
Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol.
Progress in cardiovascular diseases 1998;41(1 Suppl 1):17-24.
1998: G Feuerstein; GL Liu; Tian-Li Yue; H Y Cheng; J Paul Hieble; Jonathan R S Arch; RR Ruffolo; Xin L Ma
Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model.
European journal of pharmacology 1998;351(3):341-50.
1998: Tian-Li Yue; Xin L Ma; Juan-li Gu; RR Ruffolo; Giora Z Feuerstein
Carvedilol inhibits activation of stress-activated protein kinase and reduces reperfusion injury in perfused rabbit heart.
European journal of pharmacology 1998;345(1):61-5.
1998: Richard M Edwards; RR Ruffolo; David P Brooks
Pharmacology of the angiotensin II receptor antagonist, eprosartan.
Expert opinion on investigational drugs 1998;7(3):463-9.
1998: Tian-Li Yue; Xin L Ma; Xinkang Wang; Anne M Romanic; GL Liu; CS Louden; Juan-li Gu; S Kumar; G Poste; RR Ruffolo; Giora Z Feuerstein
Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol.
Circulation research 1998;82(2):166-74.
1998: RR Ruffolo; Giora Z Feuerstein
Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure.
European heart journal 1998;19 Suppl B():B19-24.
1998: J Paul Hieble; A Hehr; Y O Li; RR Ruffolo
Molecular basis for the stereoselective interactions of catecholamines with alpha-adrenoceptors.
Proceedings of the Western Pharmacology Society 1998;41():225-8.
1998: RR Ruffolo; Giora Z Feuerstein
Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure.
Journal of cardiovascular pharmacology 1998;32 Suppl 1():S22-30.
1998: Stephen Douglas; Ponnal Nambi; M Gellai; JI Luengo; Jia-Ning Xiang; David P Brooks; RR Ruffolo; John D Elliott; Eliot ohlstein
Pharmacologic characterization of the novel, orally available endothelin-A--selective antagonist SB 247083.
Journal of cardiovascular pharmacology 1998;31 Suppl 1():S273-6.
1998: RR Ruffolo; Giora Z Feuerstein; Eliot ohlstein
Recent observations with beta-adrenoceptor blockade. Beneficial effects in hypertension and heart failure.
American journal of hypertension 1998;11(1 Pt 2):9S-14S.
1998: Theodore A Christopher; Bernard L Lopez; Xin L Ma; Giora Z Feuerstein; RR Ruffolo; Tian-Li Yue
Effects of a hydroxylated metabolite of the beta-andrenoreceptor antagonist, carvedilol, on post-ischaemic splachnic tissue injury.
British journal of pharmacology 1998;123(2):292-8.
1998: Robert N Willette; MP Mitchell; Eliot ohlstein; M A Lukas; RR Ruffolo
Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart.
Pharmacology 1998;56(1):30-6.
1998: G Feuerstein; RR Ruffolo
Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure.
Advances in pharmacology (San Diego, Calif.) 1998;42():611-5.
1997: Giora Z Feuerstein; A Bril; RR Ruffolo
Protective effects of carvedilol in the myocardium.
The American journal of cardiology 1997;80(11A):41L-45L.
1997: Eliot ohlstein; David P Brooks; Giora Z Feuerstein; RR Ruffolo
Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
Pharmacology 1997;55(5):244-51.
1997: Giora Feuerstein; RR Ruffolo; Tian-Li Yue
Apoptosis and congestive heart failure.
Trends in cardiovascular medicine 1997;7(7):249-55.
1997: D E Griswold; RR Ruffolo; G Poste; Theodore J Torphy
Re-classification of NSAIDs.
Trends in pharmacological sciences 1997;18(9):311-2.
1997: A Hehr; J Paul Hieble; Y O Li; DJ Bergsma; A M Swift; S Ganguly; RR Ruffolo
Ser165 of transmembrane helix IV is not involved in the interaction of catecholamines with the alpha-2a-adrenoceptor.
Pharmacology 1997;55(1):18-24.
1997: Xin L Ma; Bernard L Lopez; GL Liu; Theodore A Christopher; Feng Gao; Y Guo; Giora Z Feuerstein; RR Ruffolo; Frank C Barone; Tian-Li Yue
Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury.
Circulation research 1997;80(6):894-901.
1997: RR Ruffolo; Giora Z Feuerstein
Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 1997;11 Suppl 1():247-56.
1997: J Paul Hieble; RR Ruffolo
Recent advances in the identification of alpha1- and alpha2-adrenoceptor subtypes: therapeutic implications.
Expert opinion on investigational drugs 1997;6(4):367-87.
1996: Ponnal Nambi; Mark A Pullen; HL Wu; D Lee; D Saunders; R Heys; Nambi Aiyar; J Leber; J Elliott; D Brooks; Eliot ohlstein; RR Ruffolo
Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors.
The Journal of pharmacology and experimental therapeutics 1996;277(3):1567-71.
1996: Giora Z Feuerstein; RR Ruffolo
Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.
European heart journal 1996;17 Suppl B():24-9.
1996: M A Oriowo; Helen Chapman; D M Kirkham; Matthew V Sennitt; RR Ruffolo; Michael A Cawthorne
The selectivity in vitro of the stereoisomers of the beta-3 adrenoceptor agonist BRL 37344.
The Journal of pharmacology and experimental therapeutics 1996;277(1):22-7.
1996: Xin L Ma; Tian-Li Yue; Bernard L Lopez; F C Barone; Theodore A Christopher; RR Ruffolo; Giora Z Feuerstein
Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits.
The Journal of pharmacology and experimental therapeutics 1996;277(1):128-36.
1996: J Paul Hieble; RR Ruffolo
Subclassification and nomenclature of alpha 1- and alpha 2-adrenoceptors.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques 1996;47():81-130.
1995: Tian-Li Yue; X Wang; Juan-li Gu; RR Ruffolo; Giora Z Feuerstein
Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyte adhesion to endothelial cells by inhibition of LDL oxidation.
European journal of pharmacology 1995;294(2-3):585-91.
1995: X Wang; Tian-Li Yue; Frank C Barone; Ray F White; R K Clark; Robert N Willette; Anthony C Sulpizio; Nambi Aiyar; RR Ruffolo; Giora Z Feuerstein
Discovery of adrenomedullin in rat ischemic cortex and evidence for its role in exacerbating focal brain ischemic damage.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(25):11480-4.
1995: RR Ruffolo; WE Bondinell; J Paul Hieble
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.
Journal of medicinal chemistry 1995;38(19):3681-716.
1995: J Paul Hieble; WE Bondinell; RR Ruffolo
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
Journal of medicinal chemistry 1995;38(18):3415-44.
1995: Bernard L Lopez; Theodore A Christopher; Tian-Li Yue; RR Ruffolo; Giora Z Feuerstein; Xin L Ma
Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction.
Pharmacology 1995;51(3):165-73.
1995: J Paul Hieble; RR Ruffolo
Possible structural and functional relationships between imidazoline receptors and alpha 2-adrenoceptors.
Annals of the New York Academy of Sciences 1995;763():8-21.
1995: Giora Z Feuerstein; RR Ruffolo
Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection.
European heart journal 1995;16 Suppl F():38-42.
1995: Tian-Li Yue; X Wang; Juan-li Gu; RR Ruffolo; Giora Z Feuerstein
Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells.
The Journal of pharmacology and experimental therapeutics 1995;273(3):1442-9.
1995: Theodore A Christopher; Bernard L Lopez; Tian-Li Yue; Giora Z Feuerstein; RR Ruffolo; Xin L Ma
Carvedilol, a new beta-adrenoreceptor blocker, vasodilator and free-radical scavenger, exerts an anti-shock and endothelial protective effect in rat splanchnic ischemia and reperfusion.
The Journal of pharmacology and experimental therapeutics 1995;273(1):64-71.
1995: RR Ruffolo; WE Bondinell; Thomas W Ku; Diane Naselsky; J Paul Hieble
Alpha 1-adrenoceptors: pharmacological classification and newer therapeutic applications.
Proceedings of the Western Pharmacology Society 1995;38():121-6.
1994: David P Brooks; P D dePalma; M Gellai; Ponnal Nambi; Eliot ohlstein; John D Elliott; J G Gleason; RR Ruffolo
Nonpeptide endothelin receptor antagonists. III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs.
The Journal of pharmacology and experimental therapeutics 1994;271(2):769-75.
1994: Eliot ohlstein; G R Beck; Stephen Douglas; Ponnal Nambi; MA Lago; J G Gleason; RR Ruffolo; Giora Feuerstein; John D Elliott
Nonpeptide endothelin receptor antagonists. II. Pharmacological characterization of SB 209670.
The Journal of pharmacology and experimental therapeutics 1994;271(2):762-8.
1994: Ponnal Nambi; Nabil A Elshourbagy; HL Wu; Mark A Pullen; Eliot ohlstein; David P Brooks; MA Lago; John D Elliott; J G Gleason; RR Ruffolo
Nonpeptide endothelin receptor antagonists. I. Effects on binding and signal transduction on human endothelinA and endothelinB receptors.
The Journal of pharmacology and experimental therapeutics 1994;271(2):755-61.
1994: M A Oriowo; Matthew V Sennitt; Stephen A Smith; RR Ruffolo; Michael A Cawthorne
The beta-adrenoceptor selectivity profile of BRL 37344 in the pithed rat.
Journal of autonomic pharmacology 1994;14(5):337-44.
1994: Tian-Li Yue; P J Mckenna; PG Lysko; Juan-li Gu; K A Lysko; RR Ruffolo; Giora Z Feuerstein
SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant.
European journal of pharmacology 1994;251(2-3):237-43.
1994: J Paul Hieble; RR Ruffolo
Alpha 1-adrenoceptors: pharmacological subclassification and therapeutic applications.
Proceedings of the Western Pharmacology Society 1994;37():163-7.
1994: RR Ruffolo; J Paul Hieble
Alpha-adrenoceptors.
Pharmacology & therapeutics 1994;61(1-2):1-64.
1994: L B Kinter; W A Mann; J Weinstock; RR Ruffolo
Effects of catechol ring fluorination on cardiovascular and renal activities of fenoldopam enantiomers.
Chirality 1994;6(5):446-55.
1993: Tian-Li Yue; P J Mckenna; Juan-li Gu; H Y Cheng; RR Ruffolo; Giora Z Feuerstein
Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells.
Hypertension 1993;22(6):922-8.
1993: Eliot ohlstein; Stephen Douglas; C P Sung; Tian-Li Yue; CS Louden; Anthony Arleth; G Poste; RR Ruffolo; Giora Z Feuerstein
Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(13):6189-93.
1993: Giora Z Feuerstein; Tian-Li Yue; H Y Cheng; RR Ruffolo
Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1993;11(4):S41-8.
1993: David P Brooks; B G Short; M J Cyronak; Lisa C Contino; M DiCristo; Y X Wang; RR Ruffolo
Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure.
British journal of pharmacology 1993;109(2):581-6.
1993: RR Ruffolo; D A Boyle; R P Venuti; M A Lukas
Preclinical and clinical pharmacology of carvedilol.
Journal of human hypertension 1993;7 Suppl 1():S2-15.
1993: David P Brooks; P D DePalma; TA Fredrickson; W S Spielman; RR Ruffolo
Nonpeptide angiotensin II receptor antagonists: potential advantages over ACE inhibitors.
Proceedings of the Western Pharmacology Society 1993;36():25-8.
1993: RR Ruffolo; A Bril; Giora Z Feuerstein
Cardioprotective potential of carvedilol.
Cardiology 1993;82 Suppl 3():24-8.
1993: RR Ruffolo; A J Nichols; J M Stadel; J Paul Hieble
Pharmacologic and therapeutic applications of alpha 2-adrenoceptor subtypes.
Annual review of pharmacology and toxicology 1993;33():243-79.
1992: Tian-Li Yue; P J McKenna; PG Lysko; RR Ruffolo; Giora Z Feuerstein
Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper.
Atherosclerosis 1992;97(2-3):209-16.
1992: David P Brooks; P D DePalma; RR Ruffolo
Effect of captopril and the nonpeptide angiotensin II antagonists, SK&F 108566 and EXP3174, on renal function in dogs with a renal artery stenosis.
The Journal of pharmacology and experimental therapeutics 1992;263(2):422-7.
1992: Eliot ohlstein; M Gellai; David P Brooks; L Vickery; J Jugus; Anthony C Sulpizio; RR Ruffolo; J Weinstock; Richard M Edwards
The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism.
The Journal of pharmacology and experimental therapeutics 1992;262(2):595-601.
1992: David P Brooks; TA Fredrickson; J Weinstock; RR Ruffolo; Richard M Edwards; M Gellai
Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs.
Naunyn-Schmiedeberg's archives of pharmacology 1992;345(6):673-8.
1992: Tian-Li Yue; P J McKenna; RR Ruffolo; Giora Feuerstein
Carvedilol, a new beta-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils.
European journal of pharmacology 1992;214(2-3):277-80.
1992: J Paul Hieble; A J Nichols; TA Fredrickson; P D DePalma; RR Ruffolo; David P Brooks
Cardiovascular actions of a new selective postjunctional alpha-adrenoceptor antagonist, SK&F 104856, in normotensive and hypertensive dogs.
British journal of pharmacology 1992;105(4):992-6.
1992: J Paul Hieble; RR Ruffolo
Imidazoline receptors: historical perspective.
Fundamental & clinical pharmacology 1992;6 Suppl 1():7S-13S.
1992: Giora Z Feuerstein; S A Hamburger; E F Smith; A Bril; RR Ruffolo
Myocardial protection with carvedilol.
Journal of cardiovascular pharmacology 1992;19 Suppl 1():S138-41.
1992: Evangeline D Motley-Johnson; RR Ruffolo; A J Nichols
The effect of pertussis toxin treatment on alpha-1-adrenoceptor-mediated pressor responses in the pithed rat: dependence on agonist efficacy but not chemical class.
Pharmacology 1992;45(6):338-44.
1992: M A Oriowo; A J Nichols; RR Ruffolo
Receptor protection studies with phenoxybenzamine indicate that a single alpha 1-adrenoceptor may be coupled to two signal transduction processes in vascular smooth muscle.
Pharmacology 1992;45(1):17-26.
1992: A J Nichols; Paul F Koster; David P Brooks; RR Ruffolo
Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog.
The Journal of pharmacology and experimental therapeutics 1992;260(1):269-74.
1992: M A Oriowo; RR Ruffolo
Activation of a single alpha-1-adrenoceptor subtype in rat aorta mobilizes intracellular and extracellular pools of calcium.
Pharmacology 1992;44(3):139-49.
1992: M A Oriowo; RR Ruffolo
Heterogeneity of postjunctional alpha 1-adrenoceptors in mammalian aortae: subclassification based on chlorethylclonidine, WB 4101 and nifedipine.
Journal of vascular research 1992;29(1):33-40.
1992: Richard M Edwards; Nambi Aiyar; Eliot ohlstein; E F Weidley; E Griffin; M Ezekiel; Richard M Keenan; RR Ruffolo; J Weinstock
Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566.
The Journal of pharmacology and experimental therapeutics 1992;260(1):175-81.
1991: RR Ruffolo; A J Nichols; J M Stadel; J Paul Hieble
Structure and function of alpha-adrenoceptors.
Pharmacological reviews 1991;43(4):475-505.
1991: David P Brooks; M P Mitchell; B G Short; RR Ruffolo; A J Nichols
Attenuation of amphotericin B nephrotoxicity in the dog by the fenoldopam prodrug, SK&F R-105058.
The Journal of pharmacology and experimental therapeutics 1991;257(3):1243-7.
1991: RR Ruffolo; A J Nichols; M A Oriowo
Interaction of vascular alpha-1 adrenoceptors with multiple signal transduction pathways.
Blood vessels 1991;28(1-3):122-8.
1991: Evangeline D Motley-Johnson; RR Ruffolo; Douglas W P Hay; A J Nichols
Role of phosphatidylinositol turnover in the contraction of the rat aorta.
Advances in experimental medicine and biology 1991;308():211-6.
1991: David P Brooks; TA Fredrickson; Paul F Koster; RR Ruffolo
Effect of the dopamine beta-hydroxylase inhibitor, SK&F 102698, on blood pressure in the 1-kidney, 1-clip hypertensive dog.
Pharmacology 1991;43(2):90-5.
1991: A J Nichols; M Gellai; RR Ruffolo
Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol.
Fundamental & clinical pharmacology 1991;5(1):25-38.
1991: S A Hamburger; Frank C Barone; Giora Z Feuerstein; RR Ruffolo
Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction.
Pharmacology 1991;43(3):113-20.
1991: M A Oriowo; J Paul Hieble; RR Ruffolo
Evidence for heterogeneity of prejunctional alpha-2-adrenoceptors.
Pharmacology 1991;43(1):1-13.
1991: RR Ruffolo; Evangeline D Motley-Johnson; A J Nichols
The effect of pertussis toxin on alpha 1-adrenoceptor-mediated vasoconstriction by the full agonist, cirazoline, and the partial agonist, (-)-dobutamine, in pithed rats.
Fundamental & clinical pharmacology 1991;5(1):11-23.
1991: RR Ruffolo; A J Nichols; J Paul Hieble
Metabolic regulation by alpha 1- and alpha 2-adrenoceptors.
Life sciences 1991;49(3):171-83.
1990: David P Brooks; D J Drutz; RR Ruffolo
Prevention and complete reversal of cyclosporine A-induced renal vasoconstriction and nephrotoxicity in the rat by fenoldopam.
The Journal of pharmacology and experimental therapeutics 1990;254(2):375-9.
1990: A J Nichols; RR Ruffolo; David P Brooks
The pharmacology of fenoldopam.
American journal of hypertension 1990;3(6 Pt 2):116S-119S.
1990: M Gellai; R E DeWolf; RR Ruffolo
Effect of dopamine beta-hydroxylase inhibition on systemic hemodynamics in conscious, spontaneously hypertensive rats.
Pharmacology 1990;41(2):82-90.
1990: M Gellai; R DeWolf; RR Ruffolo
Effect of carvedilol on renal hemodynamics and renal excretory function in spontaneously hypertensive rats.
Pharmacology 1990;41(4):200-6.
1990: L B Kinter; E Horner; W A Mann; J Weinstock; RR Ruffolo
Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog.
Chirality 1990;2(4):219-25.
1990: RR Ruffolo; M Gellai; J Paul Hieble; R N Willette; A J Nichols
The pharmacology of carvedilol.
European journal of clinical pharmacology 1990;38 Suppl 2():S82-8.
1989: A J Nichols; Evangeline D Motley-Johnson; RR Ruffolo
Effect of pertussis toxin treatment on postjunctional alpha-1 and alpha-2 adrenoceptor function in the cardiovascular system of the pithed rat.
The Journal of pharmacology and experimental therapeutics 1989;249(1):203-9.
1989: A J Nichols; A Hamada; A Adejare; Duane D Miller; Popat N Patil; RR Ruffolo
Effect of aromatic fluorine substitution on the alpha and beta adrenoceptor-mediated effects of 3,4-dihydroxytolazoline in the pithed rat.
The Journal of pharmacology and experimental therapeutics 1989;248(2):671-6.
1989: A J Nichols; Anthony C Sulpizio; D J Ashton; J Paul Hieble; RR Ruffolo
The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors.
Chirality 1989;1(4):265-70.
1989: A J Nichols; Anthony C Sulpizio; D J Ashton; J Paul Hieble; RR Ruffolo
In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol.
Pharmacology 1989;39(5):327-36.
1989: R J Shebuski; J M Smith; RR Ruffolo
Effect of dopamine, ibopamine, and epinine on alpha- and beta-adrenoceptors in canine pulmonary circulation.
Fundamental & clinical pharmacology 1989;3(3):211-21.
1989: Eliot ohlstein; S Horohonich; R J Shebuski; RR Ruffolo
Localization and characterization of alpha-2 adrenoceptors in the isolated canine pulmonary vein.
The Journal of pharmacology and experimental therapeutics 1989;248(1):233-9.
1988: Eliot ohlstein; G A Kopia; RR Ruffolo
Coronary vascular activity of the novel inotropic pro-drug ibopamine and the de-esterified active form epinine.
Arzneimittel-Forschung 1988;38(12):1790-2.
1988: J Paul Hieble; RR Ruffolo; R N Daly
Involvement of vascular endothelium in the potentiation of vasoconstrictor responses by neuropeptide Y.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1988;6(4):S239-42.
1988: R N Daly; M I Roberts; RR Ruffolo; J Paul Hieble
The role of neuropeptide Y in vascular sympathetic neurotransmission may be enhanced in hypertension.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1988;6(4):S535-8.
1988: RR Ruffolo; A J Nichols; Popat N Patil; A Hamada; M Clark; Duane D Miller
Effects of benzylic hydroxyl substitution on the alpha-adrenoceptor blocking activity of tolazoline.
European journal of pharmacology 1988;157(2-3):235-9.
1988: J Paul Hieble; Anthony C Sulpizio; A J Nichols; Robert N Willette; RR Ruffolo
Pharmacologic characterization of SK&F 104078, a novel alpha-2 adrenoceptor antagonist which discriminates between pre- and postjunctional alpha-2 adrenoceptors.
The Journal of pharmacology and experimental therapeutics 1988;247(2):645-52.
1988: R N Daly; Anthony C Sulpizio; B Levitt; R M DeMarinis; John W Regan; RR Ruffolo; J Paul Hieble
Evidence for heterogeneity between pre- and postjunctional alpha-2 adrenoceptors using 9-substituted 3-benzazepines.
The Journal of pharmacology and experimental therapeutics 1988;247(1):122-8.
1988: G A Kopia; L J Kopaciewicz; K L Fong; C S Crysler; K Boyle; RR Ruffolo
Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog.
Journal of cardiovascular pharmacology 1988;12(3):308-16.
1988: G A Kopia; Eliot ohlstein; RR Ruffolo
Systemic and coronary hemodynamic actions of the novel inotropic agent, ibopamine, and the de-esterified metabolite and active form, epinine: relationship to left ventricular performance in the dog.
The Journal of pharmacology and experimental therapeutics 1988;246(2):434-40.
1988: I C Medgett; RR Ruffolo
Alpha adrenoceptor-mediated vasoconstriction in rat hindlimb: innervated alpha-2 adrenoceptors in the saphenous arterial bed.
The Journal of pharmacology and experimental therapeutics 1988;246(1):249-54.
1988: G A Kopia; L J Kopaciewicz; RR Ruffolo
Coronary thrombolysis with intravenous streptokinase in the anesthetized dog: a dose-response study.
The Journal of pharmacology and experimental therapeutics 1988;244(3):956-62.
1988: A J Nichols; Evangeline D Motley-Johnson; RR Ruffolo
Differential effect of pertussis toxin on pre- and postjunctional alpha 2-adrenoceptors in the cardiovascular system of the pithed rat.
European journal of pharmacology 1988;145(3):345-9.
1988: RR Ruffolo; A J Nichols
The relationship of receptor reserve and agonist efficacy to the sensitivity of alpha-adrenoceptor-mediated vasopressor responses to inhibition by calcium channel antagonists.
Annals of the New York Academy of Sciences 1988;522():361-76.
1988: R J Shebuski; J M Smith; RR Ruffolo
Comparison of the renal and pulmonary hemodynamic effects of fenoldopam, dobutamine, dopamine and norepinephrine in the anesthetized dog.
Pharmacology 1988;36(1):35-43.
1988: A J Nichols; J Paul Hieble; RR Ruffolo
The pharmacology of peripheral alpha 1- and alpha 2-adrenoceptors.
Reviews in clinical & basic pharmacology 1988;7(1-4):129-205.
1987: I C Medgett; RR Ruffolo
Characterization of alpha-adrenoceptors mediating sympathetic vasoconstriction in rat autoperfused hindlimb: effects of SK&F 104078.
European journal of pharmacology 1987;144(3):393-7.
1987: RR Ruffolo
The pharmacology of dobutamine.
The American journal of the medical sciences 1987;294(4):244-8.
1987: RR Ruffolo; Anthony C Sulpizio; A J Nichols; R M DeMarinis; J Paul Hieble
Pharmacologic differentiation between pre- and postjunctional alpha 2-adrenoceptors by SK&F 104078.
Naunyn-Schmiedeberg's archives of pharmacology 1987;336(4):415-8.
1987: A J Nichols; R J Shebuski; RR Ruffolo
Inhibition of plasma cholinesterase prevents the dopamine DA-1 receptor mediated renal vasodilation produced by ibopamine.
European journal of pharmacology 1987;141(3):515-8.
1987: A J Nichols; J M Smith; R J Shebuski; RR Ruffolo
Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
The Journal of pharmacology and experimental therapeutics 1987;242(2):573-8.
1987: RR Ruffolo; M L Cohen; K Messick; J S Horng
Alpha-2-adrenoceptor-mediated effects of pergolide.
Pharmacology 1987;35(3):148-54.
1986: G A Kopia; L J Kopaciewicz; RR Ruffolo
Alpha adrenoceptor regulation of coronary artery blood flow in normal and stenotic canine coronary arteries.
The Journal of pharmacology and experimental therapeutics 1986;239(3):641-7.
1985: RR Ruffolo; K Messick; J S Horng
Interactions of the enantiomers of 3-O-methyldobutamine with alpha- and beta-adrenoceptors in vitro.
Naunyn-Schmiedeberg's archives of pharmacology 1985;329(3):244-52.
1985: RR Ruffolo; K Messick; J S Horng
Interactions of dimethoxy-substituted tolazoline derivatives with alpha 1- and alpha 2-adrenoreceptors in vitro.
Journal of autonomic pharmacology 1985;5(1):71-9.
1984: W L Nelson; M J Bartels; P J Bednarski; S Zhang; K Messick; J S Horng; RR Ruffolo
The 3,4-catechol derivative of propranolol, a minor dihydroxylated metabolite.
Journal of medicinal chemistry 1984;27(7):857-61.
1984: RR Ruffolo; K Messick; J S Horng
Interactions of three inotropic agents, ASL-7022, dobutamine and dopamine, with alpha- and beta-adrenoceptors in vitro.
Naunyn-Schmiedeberg's archives of pharmacology 1984;326(4):317-26.